Genfit S.A. (NASDAQ:GNFT - Get Free Report) was the recipient of a large decrease in short interest in December. As of December 15th, there was short interest totalling 59,800 shares, a decrease of 6.3% from the November 30th total of 63,800 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily volume of 12,300 shares, the short-interest ratio is currently 4.9 days.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a "buy" rating and set a $13.00 target price on shares of Genfit in a research report on Friday, October 11th.
Get Our Latest Stock Analysis on GNFT
Genfit Stock Up 0.5 %
Shares of NASDAQ:GNFT traded up $0.02 during mid-day trading on Tuesday, reaching $3.71. 8,342 shares of the company traded hands, compared to its average volume of 15,487. The company's 50 day moving average price is $4.50 and its 200-day moving average price is $4.52. Genfit has a 52 week low of $3.31 and a 52 week high of $6.42. The company has a current ratio of 3.74, a quick ratio of 3.74 and a debt-to-equity ratio of 0.61.
Genfit Company Profile
(
Get Free Report)
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Recommended Stories
Before you consider Genfit, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genfit wasn't on the list.
While Genfit currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
